Literature DB >> 6365268

Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen.

D Colcher, P H Hand, M Nuti, J Schlom.   

Abstract

Splenic lymphocytes of mice immunized with membrane enriched fractions of human mammary carcinomas were fused with the NS-1 nonsecretory++ myeloma cell line. The resulting hybridomas were screened for the synthesis of immunoglobulins reactive with human mammary tumor associated antigens, and two IgG monoclonal antibodies (B1.1 and F5.5) were identified as being reactive with purified carcinoembryonic antigen (CEA). These antibodies were shown to bind to different epitopes on CEA based on their differential reactivities to five different purified CEA preparations, and their differential binding to the surface of tumor cells derived from various organ sites. Monoclonal B1.1 bound equally to the surface of human breast, colon, and melanoma cell lines. Monoclonal F5.5, on the other hand, did not react with the surface of melanoma cell lines, and showed a differential binding to breast carcinoma versus colon carcinoma cells. Monoclonals F5.5 and B1.1 were both used in immunoperoxidase studies with fixed tissue sections of a variety of histologic types of human mammary carcinomas and were shown to be reactive with 55% and 66%, respectively, of tumor masses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6365268     DOI: 10.3109/07357908309042415

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  3 in total

1.  A 3-dimensional tumor growth inhibition assay for testing monoclonal antibody cytotoxicity.

Authors:  W Z Wei; R J Massey; G H Heppner
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Monoclonal antibodies of predefined specificity detect activated ras gene expression in human mammary and colon carcinomas.

Authors:  P H Hand; A Thor; D Wunderlich; R Muraro; A Caruso; J Schlom
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

3.  Tumor-associated antigen TAG-72: correlation of expression in primary and metastatic breast carcinoma lesions.

Authors:  S C Lottich; W W Johnston; C A Szpak; E R Delong; A Thor; J Schlom
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.